Thyroid medicine recalled nationwide: FDA
Major Pharmaceuticals has issued a nationwide recall for Levothyroxine Sodium Tablets due to potency concerns. The Food and Drug Administration notes that these tablets may be subpotent, meaning they do not provide the intended effectiveness for patients treating hypothyroidism or goiter. This recall is classified as Class II, indicating that usage could result in temporary health issues.
The affected medication was distributed nationwide by Major Pharmaceuticals, with some units also supplied by Cardinal Health. Patients should check their prescription bottles to see if they are impacted by this action. The tablets were sold in 10-count blister packs, either individually or in cartons containing 100 tablets total.
Recalled dosages include 25, 50, 75, 88, 112, and 150 micrograms. Consumers should examine their medication for expiration dates ranging from July 2026 to January 2027. If you find you have these tablets, contact your healthcare provider or pharmacist for guidance on how to proceed. Do not stop taking prescribed thyroid medication without consulting a medical professional first.